(1R,3S)-3-氨基环戊烷-1-羧酸盐酸盐 | 19042-35-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1R,3S)-3-氨基环戊烷-1-羧酸盐酸盐
• 中文别名: 3-氨基环戊烷甲酸；3-氨基环戊烷甲酸(盐酸盐形式)
• 英文名称: (1R,3S)-3-aminocyclopentanecarboxylic acid hydrochloride
• 英文别名: (1R,3S)-3-aminocyclopentane-1-carboxylic acid;hydrochloride
• CAS: 19042-35-4
• 化学式: C₆H₁₁NO₂*ClH
• 分子量: 165.62
• InChiKey: YJRMNPPUVLZEIJ-JBUOLDKXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.62
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1R,3S)-3-氨基环戊烷-1-羧酸盐酸盐 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 生成 (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentanone hydrochloride
  参考文献：
  名称：

  Chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane, precursor for carbocyclic nucleoside synthesis. Dieckmann cyclization with an .alpha.-amino acid

  摘要：

  Carbocyclic nucleosides are important isosteres of nucleosides possessing a variety of antiviral and antineoplastic activities. We report here a new method for the chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane. This compound is a key precursor for the synthesis of some carbocyclic nucleosides. The method involves (1) an improved synthesis of (S)-2-aminoadipic acid; (2) Dieckmann cyclization of this alpha-amino acid to an aminocyclopentanone; and (3) elaboration of the latter to the target (1S,3R)-l-amino-3-(hydroxymethyl)cyclopentane. The starting (S)-2-aminoadipic acid delta-methyl ester was prepared enantiomerically pure from (S)-aspartic acid in 51% overall yield. Dieckmann condensation converted this amino acid to a (methoxycarbonyl)-cyclopentanone, and reduction of the ketone followed by elimination yielded (S)-3-[N-(9-phenylfluoren-9-yl)amino]-1-(methoxycarbonyl)cyclopentene. Reduction of the double bond gave a mixture of the cis and trans diastereomers. This mixture was converted to a single diastereomer by epimerization and trapping of the cis isomer as (1S,4R)-2-(9-phenylfluoren-9-yl)-2-azabicyclo[2.2.1]heptan-3-one. Hydrolytic cleavage of the lactam followed by reduction gave (IS,3R)-1-amino-3-(hydroxymethyl)-cyclopentane.

  DOI：

  10.1021/jo00061a006
• 作为产物：
  描述：

  (1S,4R)-N-(9-Phenylfluoren-9-yl)-2-azabicyclo<2.2.1>heptan-3-one 在 盐酸 、 溶剂黄146 作用下， 反应 18.0h， 生成 (1R,3S)-3-氨基环戊烷-1-羧酸盐酸盐
  参考文献：
  名称：

  Chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane, precursor for carbocyclic nucleoside synthesis. Dieckmann cyclization with an .alpha.-amino acid

  摘要：

  Carbocyclic nucleosides are important isosteres of nucleosides possessing a variety of antiviral and antineoplastic activities. We report here a new method for the chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane. This compound is a key precursor for the synthesis of some carbocyclic nucleosides. The method involves (1) an improved synthesis of (S)-2-aminoadipic acid; (2) Dieckmann cyclization of this alpha-amino acid to an aminocyclopentanone; and (3) elaboration of the latter to the target (1S,3R)-l-amino-3-(hydroxymethyl)cyclopentane. The starting (S)-2-aminoadipic acid delta-methyl ester was prepared enantiomerically pure from (S)-aspartic acid in 51% overall yield. Dieckmann condensation converted this amino acid to a (methoxycarbonyl)-cyclopentanone, and reduction of the ketone followed by elimination yielded (S)-3-[N-(9-phenylfluoren-9-yl)amino]-1-(methoxycarbonyl)cyclopentene. Reduction of the double bond gave a mixture of the cis and trans diastereomers. This mixture was converted to a single diastereomer by epimerization and trapping of the cis isomer as (1S,4R)-2-(9-phenylfluoren-9-yl)-2-azabicyclo[2.2.1]heptan-3-one. Hydrolytic cleavage of the lactam followed by reduction gave (IS,3R)-1-amino-3-(hydroxymethyl)-cyclopentane.

  DOI：

  10.1021/jo00061a006

文献信息

• Tetrahydroquinazolinone Derivatives as PARP Inhibitors
  申请人：Lupin Limited

  公开号：US20150152118A1

  公开（公告）日：2015-06-04

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R 1 -R 6 , R 7a-d , R 8a-d , A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开了式（I）的化合物，其互变异构体、立体异构体和其药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或紊乱的方法，例如癌症，这些疾病或紊乱可通过抑制受试者的PARP酶来治疗或预防。
• [EN] TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS TÉTRAHYDROQUINAZOLINONE UTILISÉS COMME INHIBITEURS DE PARP
  申请人：LUPIN LTD

  公开号：WO2014009872A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开的是式(I)的化合物，它们的互变异构体、立体异构体和药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或疾病的方法，例如癌症，通过抑制受试者的PARP酶可治疗或预防的疾病。
• [EN] INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE<br/>[FR] THIADIAZOLAMINES INDAZOLYLE ET COMPOSÉS APPARENTÉS POUR L'INHIBITION DE PROTÉINE KINASE ASSOCIÉE À RHO ET LE TRAITEMENT DE MALADIES
  申请人：LYCERA CORP

  公开号：WO2016138335A1

  公开（公告）日：2016-09-01

  The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.

  这项发明提供了吲唑基噻二唑胺及相关化合物、药物组合物、抑制Rho相关蛋白激酶的方法，以及利用这些化合物治疗炎症性疾病、免疫性疾病、纤维化疾病和其他医学疾病的方法。一种示例性的吲唑基噻二唑胺化合物是N-(5-[5-[(1H-吲唑-5-基)氨基]-1,3,4-噻二唑-2-基]吡啶-3-基)乙酰胺化合物。
• SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20190300490A1

  公开（公告）日：2019-10-03

  The present invention relates to saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds, or pharmaceutically acceptable salts thereof, having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided: wherein each substituent is defined as defined in the description.

  本发明涉及具有RORγ拮抗活性的饱和环融合二氢嘧啶酮或二氢三唑酮化合物，或其药学上可接受的盐，包括这些化合物的药物组合物，以及其药用。提供了Formula [I]的化合物或其药学上可接受的盐，包括含有相同化合物的药物组合物，以及其药用：其中每个取代基的定义如描述中所定义。
• Divergent Synthesis of γ‐Amino Acid and γ‐Lactam Derivatives from<i>meso</i>‐Glutaric Anhydrides
  作者：Simon N. Smith、Ryan Craig、Stephen J. Connon

  DOI：10.1002/chem.202003280

  日期：2020.10.21

  The first divergent synthesis of both γ‐amino acid and γ‐lactam derivatives from meso‐glutaric anhydrides is described. The organocatalytic desymmetrisation with TMSN3 relies on controlled generation of a nucleophilic ammonium azide species mediated by a polystyrene‐bound base to promote efficient silylazidation. After Curtius rearrangement of the acyl azide intermediate to access the corresponding

  描述了由内消旋戊二酸酐合成γ-氨基酸和γ-内酰胺衍生物的第一种方法。TMSN 3的有机催化去对称性依赖于受控生成的聚苯乙烯键合碱介导的亲核叠氮化铵物种，以促进有效的甲硅烷基叠氮化。将酰基叠氮化物中间体进行Curtius重排以得到相应的异氰酸酯后，水解/醇解可提供均匀高收率的γ-氨基酸及其N受保护的同行。结果表明，相同的中间体原位经历了前所未有的脱羧-环化级联反应，无需使用任何其他活化剂即可提供合成有用的γ-内酰胺衍生物。机械学的见解在后一个过程中调用了非常规的γ- N-羧基酸酐（γ-NCA）的中介作用。在使用这种转化方法制备的实例中，有8种具有重大医学意义的API /分子。